{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:30:09Z","timestamp":1791599409772,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Malaysia Ministry of Higher Education","doi-asserted-by":"publisher","award":["FRGS\/1\/2022\/STG04\/UM\/02\/1"],"award-info":[{"award-number":["FRGS\/1\/2022\/STG04\/UM\/02\/1"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004386","name":"Universiti Malaya","doi-asserted-by":"publisher","award":["IIRG001C\\u20132022FNW"],"award-info":[{"award-number":["IIRG001C\\u20132022FNW"]}],"id":[{"id":"10.13039\/501100004386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118135","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T10:02:24Z","timestamp":1757757744000},"page":"118135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Overcoming EGFR mutation resistance: Dual inhibition strategies using TKIs in non-small cell lung cancer therapy"],"prefix":"10.1016","volume":"300","author":[{"given":"Jeevitha","family":"Sivam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhar","family":"Ariffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajantha","family":"Sinniah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Norazit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2355-9926","authenticated-orcid":false,"given":"Muhammad Kumayl","family":"Abdulwahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118135_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115335","article-title":"Discovery of a novel dual functional phenylpyrazole-styryl hybrid that induces apoptotic and autophagic cell death in bladder cancer cells","volume":"254","author":"Leong","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","article-title":"EGFR mutations and lung cancer","volume":"6","author":"da Cunha Santos","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejmech.2025.118135_bib3","article-title":"Biochemistry, epidermal growth factor receptor","author":"Murphrey","year":"2024","journal-title":"StatPearls"},{"key":"10.1016\/j.ejmech.2025.118135_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112640","article-title":"Novel quinazoline-based EGFR kinase inhibitors: a review focussing on SAR and molecular docking studies (2015-2019)","volume":"204","author":"Bhatia","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib5","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1021\/acs.jmedchem.1c01714","article-title":"Development of dual inhibitors targeting epidermal growth factor receptor in cancer therapy","volume":"65","author":"Tan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.21037\/tlcr.2019.04.12","article-title":"Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment","volume":"8","author":"Zhang","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118135_bib7","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.21037\/tcr-23-956","article-title":"Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118135_bib8","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/cmdc.202100166","article-title":"Next-generation kinase inhibitors targeting specific biomarkers in non-small cell lung cancer (NSCLC): a recent overview","volume":"16","author":"Das","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118135_bib9","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1039\/D4MD00384E","article-title":"Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019\u20132024)","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","article-title":"Emerging strategies to overcome resistance to third-generation EGFR inhibitors","volume":"15","author":"Shi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118135_bib11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1039\/C7MD00097A","article-title":"An insight on therapeutic potential of quinazoline derivatives as anticancer agents","volume":"8","author":"Shagufta","year":"2017","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.ejmech.2025.118135_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106057","article-title":"Overcoming C797S mutation: the challenges and prospects of the fourth-generation EGFR-TKIs","volume":"128","author":"Zhao","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib13","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/med.21488","article-title":"Targeting EGFR (L858R\/T790M) and EGFR (L858R\/T790M\/C797S) resistance mutations in NSCLC: current developments in medicinal chemistry","volume":"38","author":"Lu","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118135_bib14","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2025.118135_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.922839","article-title":"Uncovering the mechanism of drug resistance caused by the T790M mutation in EGFR kinase from absolute binding free energy calculations","volume":"9","author":"Zhou","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2025.118135_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118135_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lungcan.2019.09.017","article-title":"Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)","volume":"137","author":"Gelatti","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2025.118135_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","article-title":"Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer","volume":"79","author":"Murtuza","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118135_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000060","article-title":"Mechanisms of resistance to EGFR-targeted drugs: lung cancer","volume":"1","author":"Morgillo","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejmech.2025.118135_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40487-018-0061-y","article-title":"Osimertinib for previously treated patients with advanced EGFR T790M mutation-positive NSCLC: tolerability and diagnostic methods from an expanded access program","volume":"6","author":"Santos","year":"2018","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.ejmech.2025.118135_bib21","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118135_bib22","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/cancers11030366","article-title":"Newer-generation EGFR inhibitors in lung cancer: how are they best used?","volume":"11","author":"L\u00ea","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118135_bib23","doi-asserted-by":"crossref","first-page":"90557","DOI":"10.18632\/oncotarget.21164","article-title":"Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118135_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ph13100273","article-title":"Epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC)","volume":"13","author":"O'Leary","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118135_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103225","article-title":"Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective","volume":"159","author":"Lai-Kwon","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2025.118135_bib26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4155\/fmc-2016-0019","article-title":"Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR","volume":"8","author":"Lim","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40364-019-0179-6","article-title":"Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer","volume":"7","author":"Zhang","year":"2019","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ejmech.2025.118135_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118135_bib29","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4155\/fmc-2016-0019","article-title":"Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR","volume":"8","author":"Lim","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib30","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.3390\/cancers13184641","article-title":"Histologic transformation in EGFR-mutant lung adenocarcinomas: mechanisms and therapeutic implications","volume":"13","author":"Pathak","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118135_bib31","first-page":"3189","article-title":"Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors","volume":"11","author":"Qiu","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118135_bib32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118135_bib33","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.3390\/cancers13163949","article-title":"The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review","volume":"13","author":"Rascio","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118135_bib34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.12998\/wjcc.v6.i11.418","article-title":"Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: history and status","volume":"6","author":"Kanat","year":"2018","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.ejmech.2025.118135_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12885-022-10428-3","article-title":"Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer","volume":"23","author":"Harada","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2025.118135_bib36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: implications for combining anti\u2013VEGF and anti\u2013EGFR agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118135_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116265","article-title":"Design, synthesis, and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway","volume":"43","author":"Wang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib38","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jjco\/hyad052","article-title":"Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance","volume":"53","author":"Araki","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118135_bib39","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118135_bib40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/23120541.00239-2022","article-title":"Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer","volume":"8","author":"Gijtenbeek","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ejmech.2025.118135_bib41","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3390\/cancers14092157","article-title":"Treatment-related adverse events of combination EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor in EGFR-mutant advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"14","author":"Chan","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118135_bib42","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jtho.2022.01.012","article-title":"Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a Phase 1b, open-label, multicenter trial","volume":"17","author":"Ahn","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.118135_bib43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118135_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106938","article-title":"Novel quinazoline-based dual EGFR\/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: design, synthesis, and anti-tumor activity","volume":"142","author":"Zhang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111607","article-title":"1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI-resistant NSCLC","volume":"182","author":"Dokla","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115939","article-title":"Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR\/c-Met inhibitors for the treatment of NSCLC","volume":"263","author":"Tang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26103041","article-title":"Design, synthesis, and antitumor activity of olmutinib derivatives containing acrylamide moiety","volume":"26","author":"Hu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118135_bib48","doi-asserted-by":"crossref","first-page":"24858","DOI":"10.1021\/acsomega.2c03079","article-title":"Synthesis and antiproliferative activity of a new series of mono- and bis(dimethylpyrazolyl)-s-triazine derivatives targeting EGFR\/PI3K\/AKT\/mTOR signaling cascades","volume":"7","author":"Shawish","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.118135_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127045","article-title":"Design and synthesis of a novel class EGFR\/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold","volume":"30","author":"Sun","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118135_bib50","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.bioorg.2018.07.015","article-title":"Dual EGFR\/HER2 inhibitors and apoptosis inducers: new benzo[g]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers","volume":"80","author":"Ghorab","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118135_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128703","article-title":"Synthesis and biological evaluation of new series of quinazoline derivatives as EGFR\/HER2 dual-target inhibitors","volume":"67","author":"Jiao","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118135_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135165","article-title":"Design, synthesis, and antiproliferative properties of new 1,2,3-triazole-carboximidamide derivatives as dual EGFR\/VEGFR-2 inhibitors","volume":"1282","author":"Mahmoud","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118135_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-73171-8","article-title":"Novel quinazolin-4-one-based derivatives bearing 1,2,3-triazole and glycoside moieties as potential cytotoxic agents through dual EGFR and VEGFR-2 inhibitory activity","volume":"14","author":"Abdel-Rahman","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118135_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119531","article-title":"EGFR\/VEGFR-2 dual inhibitor and apoptotic inducer: design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4-one derivatives","volume":"277","author":"Mourad","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.118135_bib55","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.3390\/molecules27123906","article-title":"Discovery of novel quinazoline derivatives as potent antitumor agents","volume":"27","author":"Niu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118135_bib56","article-title":"Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives","volume":"2014","author":"Asif","year":"2014","journal-title":"Int. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:04:12Z","timestamp":1772841852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":56,"alternative-id":["S0223523425009006"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118135","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming EGFR mutation resistance: Dual inhibition strategies using TKIs in non-small cell lung cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118135"}}